• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by PLUS THERAPEUTICS Inc.

    5/15/26 6:45:36 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care
    Get the next $PSTV alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    PLUS THERAPEUTICS, INC.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)




    72941H806

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    72941H806


    1Names of Reporting Persons

    Highbridge Capital Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    13,157,894.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    13,157,894.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    13,157,894.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.1 %
    12Type of Reporting Person (See Instructions)

    IA, OO

    Comment for Type of Reporting Person:  Reflects shares of Common Stock (as defined in Item 2(a)) issuable upon exercise of warrants.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    PLUS THERAPEUTICS, INC.
    (b)Address of issuer's principal executive offices:

    6420 Levit Green Boulevard, Suite 310, Houston, Texas 77021
    Item 2. 
    (a)Name of person filing:

    This statement is filed by Highbridge Capital Management, LLC ("Highbridge" or the "Reporting Person"), a Delaware limited liability company and the investment adviser to certain funds and accounts (the "Highbridge Funds"), with respect to the common stock, par value $0.001 per share ("Common Stock") of Plus Therapeutics, Inc., a Delaware corporation (the "Issuer"), issuable upon exercise of warrants directly held by the Highbridge Funds; The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
    (b)Address or principal business office or, if none, residence:

    The address of the business office of the Reporting Person is 390 Madison Avenue, 28th Floor, New York, NY 10017.
    (c)Citizenship:

    Highbridge is a Delaware limited liability company.
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP Number(s):

    72941H806
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 171,550,698 shares of Common Stock outstanding as of March 18, 2026, as reported in the Issuer's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on March 31, 2026, and assumes the exercise of the warrants held by the Highbridge Funds.
    (b)Percent of class:

    7.1%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See Item 2(a). The Highbridge Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein. Highbridge Tactical Credit Master Fund, L.P., a Highbridge Fund, has the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of more than 5% of the outstanding Common Stock.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Highbridge Capital Management, LLC
     
    Signature:/s/ Kirk Rule
    Name/Title:Kirk Rule, Executive Director
    Date:05/15/2026
    Get the next $PSTV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PSTV

    DatePrice TargetRatingAnalyst
    2/3/2026$2.00Buy
    Lake Street
    9/3/2025$5.00Hold → Buy
    D. Boral Capital
    3/17/2025$9.00Buy
    D. Boral Capital
    More analyst ratings

    $PSTV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Plus Therapeutics with a new price target

    Lake Street initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $2.00

    2/3/26 8:52:26 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics upgraded by D. Boral Capital with a new price target

    D. Boral Capital upgraded Plus Therapeutics from Hold to Buy and set a new price target of $5.00

    9/3/25 8:18:22 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    D. Boral Capital initiated coverage on Plus Therapeutics with a new price target

    D. Boral Capital initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $9.00

    3/17/25 7:41:57 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases

    Plus and Harvard analysis shows CNSide enables early diagnosis and better clinical decision-making reducing healthcare costs by 40% Presentation receives blue-ribbon recognition at the ISPOR Annual Meeting, the premier global gathering for health economics and outcomes research HOUSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced the presentation of a new health economics study evaluating the economic impact of earlier detection and therapeutic management of LM using the CNSide ce

    5/26/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology

    Partnership to deliver a novel AI-native integrated CNS oncology platform Platform will unify and analyze Plus' proprietary therapeutic, diagnostic, and bioinformatics datasets to accelerate precision neuro-oncology HOUSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics for central nervous system (CNS) cancers, today announces that it has signed an agreement to enter into a strategic partnership with Ephemeral Technologies ("Ephemeral") to deliver a unique AI execution platform for CNS oncology. The AI execution platform is designed to integrate, organize, and derive ac

    5/19/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout

    HOUSTON, May 15, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces financial results for the first quarter ended March 31, 2026 and provides an overview of recent and upcoming business highlights. "Our team remains focused on our two highest-priority 2026 goals, CNSide commercial scale-up and REYOBIQ pivotal-trial readiness," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "We continue to add payers for CNSide, including a fourth national payer, expanding cov

    5/15/26 4:05:00 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Van Es-Johansson An

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    5/18/26 4:13:37 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Hawkins Richard J

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    5/18/26 4:12:10 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Guse Kyle

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    5/18/26 4:11:53 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    SEC Filings

    View All

    SEC Form S-3 filed by PLUS THERAPEUTICS Inc.

    S-3 - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

    6/1/26 8:58:20 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    PLUS THERAPEUTICS Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

    5/15/26 4:46:48 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    PLUS THERAPEUTICS Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

    5/15/26 4:13:11 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Sims Andrew John Hugh Macintyre bought $10,200 worth of shares (20,000 units at $0.51), increasing direct ownership by 42% to 68,138 units (SEC Form 4)

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    11/5/25 8:30:03 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Director Lenk Robert P bought $53,779 worth of shares (110,000 units at $0.49), increasing direct ownership by 375% to 139,327 units (SEC Form 4)

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    8/25/25 7:30:05 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Director Hawkins Richard J bought $5,996 worth of shares (4,000 units at $1.50), increasing direct ownership by 36% to 15,188 units (SEC Form 4)

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    9/17/24 7:00:04 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by PLUS THERAPEUTICS Inc.

    SC 13G - PLUS THERAPEUTICS, INC. (0001095981) (Subject)

    6/5/24 7:26:01 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by PLUS THERAPEUTICS Inc. (Amendment)

    SC 13G/A - PLUS THERAPEUTICS, INC. (0001095981) (Subject)

    2/13/23 3:25:03 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by PLUS THERAPEUTICS Inc. (Amendment)

    SC 13G/A - PLUS THERAPEUTICS, INC. (0001095981) (Subject)

    2/11/22 7:53:23 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    Financials

    Live finance-specific insights

    View All

    Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™

    HOUSTON, April 23, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announced today the initiation of manufacturing activities and technology transfer with SpectronRx under a previously executed Master Services Agreement (MSA), in support of late-stage clinical manufacturing of Rhenium-186 and REYOBIQ. With SpectronRx serving as a second GMP manufacturing site alongside Radiomedix, and Rhenium-186 isotope supplied through Telix Pharmaceuticals, Plus strengthens the reliability of its multi-partner supply chain

    4/23/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption

    HOUSTON, April 07, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that the American Medical Association (AMA) has approved a new, Proprietary Laboratory Analyses (PLA) Current Procedural Terminology (CPT) code for its CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) test. The dedicated billing code, 0640U, effective July 1, 2026, establishes a unique reimbursement identifier for the CNSide CSF TCE test, supporting payer claims processing and facilitating broader clinical adoptio

    4/7/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%

    HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the presentation of a new health economics study evaluating the economic impact of earlier detection and therapeutic management of LM using the CNSide cerebrospinal fluid (CSF) assay. The cost-of-care analysis suggests that earlier LM diagnosis and therapeutic management enabled by CNSide may reduce overall LM-related healthcare costs by approximately 40%, primarily through earlier therapeutic intervention, improved treatment precisio

    3/19/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    Leadership Updates

    Live Leadership Updates

    View All

    Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    HOUSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that it has granted inducement awards to Eric J Daniels, M.D., its new Chief Development Officer who joined the Company on April 20, 2026. The awards were granted on April 20, 2026 under the Company's 2015 New Employee Incentive Plan, as amended, which provides for the granting of equity awards to new employees as an inducement to join the Company. The inducement awards consist of options to purchase 20,000 shares of the Company common

    4/22/26 4:30:00 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution

    HOUSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the appointment of Randy H. Goodman, Ph.D., M.H.A., as Vice President, Value Strategy & Health Economics and Outcomes Research (HEOR), effective April 13th, 2026. Dr. Goodman is a highly experienced health economics and market access leader with more than 20 years of experience spanning global pricing and reimbursement strategy, real-world evidence generation, and value-based healthcare modeling across the biotechnology, pharmaceutic

    4/15/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline

    HOUSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced the appointment of Eric J. Daniels, M.D., MBA, as Chief Development Officer, effective April 20, 2026. Dr. Daniels is a seasoned biotechnology executive with more than two decades of experience spanning clinical development, regulatory strategy, corporate operations, and business development. He most recently served as Chief Development Officer at Kiora Pharmaceuticals , where he oversaw the company's full development portfolio

    4/9/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care